PTSD Clinical Trial
Official title:
A 12-Week, Open-Label, Multicenter, Extension Study To TNX-CY-P201 To Evaluate The Safety And Efficacy Of TNX-102 SL Taken Daily At Bedtime In Patients With Military-Related PTSD And Related Conditions
This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition. Patients recruited into this trial are those who have successfully completed the double-blind study, TNX-CY-P201 (AtEase Study). Patients will not be made aware of the therapy they received during the double-blind study.
The study will consist of 4 clinic visits, including Screening/Baseline Visit 1 (Day 0, which
is anticipated to be the same date as the final visit in the lead-in P201 study) and visits
after 2, 6 and 12 weeks of treatment. The previous requirements in the lead-in study for
refraining from the use of certain concomitant medications and trauma-focused psychotherapies
will be relaxed. Patients may continue to take rescue therapy for sleep, as appropriate, or
they may utilize other medications as needed to help them sleep, per the judgment of the
investigator.
Eligible patients who provide written informed consent will take one TNX-102 SL tablet daily
at bedtime sublingually (under the tongue) for 12 weeks. All patients will be assigned to
receive tthe same dosage of TNX-102 SL, regardless of their treatment assignment in the
lead-in study. No patients, investigators, or study staff will know the assigned study
treatment from the lead-in study, P201, at the time of entry into the extension study.
Patient data collected at the Week 12 visit (Visit 9) in the lead-in P201 study will be used
as one of the baseline values for this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03962504 -
Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial
|
N/A | |
| Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
| Not yet recruiting |
NCT06278922 -
Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma
|
N/A | |
| Completed |
NCT04597450 -
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
| Completed |
NCT03593772 -
Mission Reconnect- Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD
|
N/A | |
| Completed |
NCT03429166 -
Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas
|
N/A | |
| Recruiting |
NCT04317820 -
Deep Brain Reorienting in Post-traumatic Stress Disorder
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT03504722 -
Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD
|
N/A | |
| Completed |
NCT04305353 -
Intensive Care Unit (ICU) Diary Project
|
N/A | |
| Completed |
NCT03113890 -
McLean and Genomind Prospective Study
|
N/A | |
| Withdrawn |
NCT05173831 -
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans
|
Phase 2 | |
| Withdrawn |
NCT03924297 -
Chilipad for Sleep and Symptoms of PTSD
|
N/A | |
| Not yet recruiting |
NCT04056767 -
Changes in Digital Phenotype During PE Therapy
|
||
| Withdrawn |
NCT03216356 -
Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD
|
Phase 2/Phase 3 | |
| Completed |
NCT03343028 -
Biomarker Establishment for Superior Treatment of PTSD
|
||
| Completed |
NCT03158558 -
Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD
|
N/A | |
| Completed |
NCT02370173 -
A Non-Pharmacological Method for Enhancing Sleep in PTSD
|
N/A | |
| Withdrawn |
NCT01957371 -
Mindful Yoga Therapy for Veterans With PTSD and Pain
|
N/A | |
| Completed |
NCT01911585 -
Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure
|
N/A |